JP2025506001A5 - - Google Patents
Info
- Publication number
- JP2025506001A5 JP2025506001A5 JP2024546261A JP2024546261A JP2025506001A5 JP 2025506001 A5 JP2025506001 A5 JP 2025506001A5 JP 2024546261 A JP2024546261 A JP 2024546261A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2025506001 A5 JP2025506001 A5 JP 2025506001A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- chelating agent
- salt
- mbq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263308211P | 2022-02-09 | 2022-02-09 | |
| US63/308,211 | 2022-02-09 | ||
| PCT/IB2023/051159 WO2023152671A1 (en) | 2022-02-09 | 2023-02-09 | Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506001A JP2025506001A (ja) | 2025-03-05 |
| JP2025506001A5 true JP2025506001A5 (cg-RX-API-DMAC7.html) | 2026-02-06 |
Family
ID=85328574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024546261A Pending JP2025506001A (ja) | 2022-02-09 | 2023-02-09 | 225-アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250161502A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475900A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506001A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118647415A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023152671A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2025058000A1 (cg-RX-API-DMAC7.html) | 2023-09-13 | 2025-03-20 | ||
| WO2025218879A1 (en) * | 2024-04-15 | 2025-10-23 | Itm Technologies Munich Se | Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same |
| WO2025255396A1 (en) * | 2024-06-05 | 2025-12-11 | Ariceum Therapeutics Gmbh | Radiopharmaceutical composition and methods |
| WO2026089608A2 (en) | 2024-10-21 | 2026-04-30 | Erasmus University Medical Center Rotterdam | Radiopharmaceuticals |
| WO2026120497A1 (en) * | 2024-12-05 | 2026-06-11 | Novartis Ag | Stable radionuclide complex solutions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1606012A2 (en) * | 2003-03-25 | 2005-12-21 | Sloan-Kettering Institute For Cancer Research | Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy |
| KR20250057132A (ko) | 2016-03-22 | 2025-04-28 | 더 존스 홉킨스 유니버시티 | 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제 |
| US11478558B2 (en) * | 2017-05-30 | 2022-10-25 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| PL3997103T3 (pl) | 2019-07-08 | 2025-03-24 | 3B Pharmaceuticals Gmbh | Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie |
| CN118955620A (zh) | 2019-07-08 | 2024-11-15 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| CA3185968A1 (en) * | 2020-07-13 | 2022-01-20 | Tony Lahoutte | Antibody fragment against folr1 |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4274835A1 (en) | 2021-01-07 | 2023-11-15 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4122499A1 (en) | 2021-07-23 | 2023-01-25 | 3B Pharmaceuticals GmbH | Fibroblast activation protein inhibitors and use thereof |
-
2023
- 2023-02-09 EP EP23706856.4A patent/EP4475900A1/en active Pending
- 2023-02-09 WO PCT/IB2023/051159 patent/WO2023152671A1/en not_active Ceased
- 2023-02-09 CN CN202380018997.0A patent/CN118647415A/zh active Pending
- 2023-02-09 US US18/836,576 patent/US20250161502A1/en active Pending
- 2023-02-09 JP JP2024546261A patent/JP2025506001A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Laere et al. | Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside | |
| Westrøm et al. | Preparation of 212Pb-labeled monoclonal antibody using a novel 224Ra-based generator solution | |
| JP2025183243A (ja) | 安定な濃厚放射性核種錯体溶液 | |
| JP2023552180A5 (cg-RX-API-DMAC7.html) | ||
| JP2025506322A (ja) | 放射性核種錯体の大規模合成のための方法 | |
| JP2025111424A5 (cg-RX-API-DMAC7.html) | ||
| US20090155167A1 (en) | Automated method | |
| JP2023117417A5 (cg-RX-API-DMAC7.html) | ||
| RS66467B1 (sr) | Kompleks koji se sastoji iz jedinjenja koje cilja psma vezano sa radionuklidom olova ili torijuma | |
| US20250127940A1 (en) | Radiopharmaceutical and methods | |
| Le Fur et al. | Pyclen tri-n-butylphosphonate ester as potential chelator for targeted radiotherapy: from yttrium (III) complexation to 90Y radiolabeling | |
| AU2024227297A1 (en) | Methods for radiolabeling PSMA binding ligands and their kits | |
| Matazova et al. | Insights into actinium complexes with tetraacetates─ AcBATA versus AcDOTA: thermodynamic, structural, and labeling properties | |
| US20250145664A1 (en) | Pharmaceutical compositions for imaging, diagnosis and treatment of cancer | |
| Holland | The radiochemistry of zirconium | |
| WO2026025213A1 (zh) | 一种含rgd多肽的组合物及其应用 | |
| Srivastava et al. | Targeted Radiopharmaceuticals and Imaging: Development Challenges and Opportunities | |
| RU2859685C2 (ru) | Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC | |
| Pandey et al. | Advances in Targeted Radiopharmaceuticals: Challenges and Opportunities | |
| WO2025030160A1 (en) | Chelating compounds and methods of uses thereof | |
| AU2023227218A1 (en) | Radiopharmaceutical and methods | |
| Notation | Radioactivity, Radionuclides, and Radiopharmaceuticals | |
| Test | Asian Journal of Medical Radiological Research Original Article |